Breaking News Instant updates and real-time market news.

PFE

Pfizer

$36.41

-0.04 (-0.11%)

, AGLE

Aeglea BioTherapeutics

$5.25

0.18 (3.55%)

04:55
01/10/18
01/10
04:55
01/10/18
04:55

EBD Group to hold a conference

Biotech Showcase 2018 is being held in San Francisco on January 8-10.

PFE

Pfizer

$36.41

-0.04 (-0.11%)

AGLE

Aeglea BioTherapeutics

$5.25

0.18 (3.55%)

BMRN

BioMarin

$89.14

0.505 (0.57%)

RXII

RXi Pharmaceuticals

$4.41

-0.0999 (-2.22%)

NAVB

Navidea

$0.39

(0.00%)

CLRB

Cellectar Biosciences

$1.19

-0.0601 (-4.81%)

EBIO

Eleven Biotherapeutics

$0.86

-0.0102 (-1.17%)

PSDV

pSivida

$1.10

(0.00%)

VTGN

VistaGen Therapeutics

$1.19

0.08 (7.21%)

SPHS

Sophiris Bio

$2.27

-0.13 (-5.42%)

ABMD

Abiomed

$209.76

1.96 (0.94%)

AYTU

Aytu BioScience

$2.36

-0.11 (-4.45%)

TROV

Trovagene

$0.34

-0.0175 (-4.90%)

KOOL

Cesca Therapeutics

$3.79

0.4383 (13.08%)

SFE

Safeguard Scientifics

$11.05

(0.00%)

  • 10

    Jan

  • 25

    Jan

  • 30

    Jan

  • 01

    Feb

  • 06

    Feb

  • 08

    Feb

  • 16

    Feb

  • 28

    Feb

  • 25

    May

PFE Pfizer
$36.41

-0.04 (-0.11%)

12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/13/17
PIPR
11/13/17
NO CHANGE
Target $54
PIPR
Overweight
Pfizer still most compelling risk/reward in global pharma, says Piper Jaffray
Piper Jaffray analyst Richard Purkis says Pfizer remains the most compelling long-run risk/reward opportunity in his global pharma coverage universe. He believes the company's key growth assets, or Ibrance, Eliquis, Xtandi, Xeljanz and Bosulif, and pipeline are being underestimated by investors. Pfizer remains one of the analyst's top 2017 picks. Purkis reiterates an Overweight rating on the shares with a $54 price target.
AGLE Aeglea BioTherapeutics
$5.25

0.18 (3.55%)

BMRN BioMarin
$89.14

0.505 (0.57%)

12/18/17
MSCO
12/18/17
NO CHANGE
MSCO
Morgan Stanley sees opportunities in biotech amid 'limited' investor conviction
With clinical catalysts in large-cap Biotechnology limited to only five key Phase III readouts - three of which are from Alexion (ALXN) - investors are describing their 2018 picks in the space as the "least worst" of the group, according to Morgan Stanley analyst Matthew Harrison. However, he believes this lack of conviction creates real opportunity for outsized moves in 2018, with Amgen (AMGN) identified by Harrison as the biggest potential beneficiary of M&A given "its likely newfound access" to about $39B in offshore cash. Other biotech names the analyst highlights on the up side include Biogen (BIIB), BioMarin (BMRN), Biohaven (BHVN) and Sarepta (SRPT). Meanwhile, Harrison highlights his concerns about potential downside for BioVerativ (BIVV) and Innoviva (INVA), on both of which he keeps Underweight ratings.
12/18/17
SBSH
12/18/17
NO CHANGE
SBSH
Citi downgrades stance on large-cap Biotechnology to Neutral
Citi analyst Robyn Karnauskas downgraded her view on the large-cap Biotechnology sector to Neutral heading into 2018. The negative sentiment on the space may not change in the near term as valuations are not cheap and there are few catalysts in 2018, Karnauskas tells investors in a research note. Valuations in the group do not appear cheap when you look at the growth profile of large-cap biotech versus the broader market, the analyst contends. She believes the "only way out for the sector is innovation," and prefers to move to the sidelines "until we see something there." Where Karnauskas does see upside in 2018 is in shares of Alexion (ALXN), BioMarin (BMRN), Vertex (VRTX) and Tesaro (TSRO).
12/15/17
12/15/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Foot Locker (FL) upgraded to Buy from Hold by Canaccord analyst Camilo Lyon, who believes the company is approaching the end of the inventory clearance cycle it has been in for the past three quarters and that the company's relationship with Nike (NKE) is "strong and symbiotic." 2. Stifel analyst Jim Duffy upgraded Under Armour (UAA) to Buy from Hold, saying he expects the company's business to be in a much better position entering 2019 and for the stock to begin to anticipate improvements before it shows in reported results. 3. Argus analyst John Staszak upgraded Skechers (SKX) to Buy from Hold with a price target of $44, citing signs that a recovery in the company's domestic wholesale business has commenced. 4. Goldman analyst Robert Jones upgraded AmerisourceBergen (ABC) to Buy from Neutral, telling investors he believes an EBIT inflection in FY18 is coming. 5. Goldman Sachs analyst Jami Rubin added BioMarin (BMRN) and Alnylam (ALNY) to the firm's Conviction Buy List, upgrading them both from Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/15/17
GSCO
12/15/17
UPGRADE
Target $131
GSCO
Conviction Buy
BioMarin upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Jami Rubin added BioMarin to the Conviction Buy List saying shares are poised to recover. Rubin expects BioMarin shares to be driven by an increasing base business of six orphan drugs driving FY17 guidance of $1.25B-$1.3B and peak sales of $2.4B in 2026, the broad pipeline with three pivotal programs that can contribute $2.8B in peak sales in 2026 and early programs not reflected in projections, non-GAAP profitability by year-end 2017, and an attractive M&A profile. The analyst has a $131 price target on BioMarin shares.
RXII RXi Pharmaceuticals
$4.41

-0.0999 (-2.22%)

NAVB Navidea
$0.39

(0.00%)

CLRB Cellectar Biosciences
$1.19

-0.0601 (-4.81%)

EBIO Eleven Biotherapeutics
$0.86

-0.0102 (-1.17%)

PSDV pSivida
$1.10

(0.00%)

06/13/17
LTCO
06/13/17
NO CHANGE
Target $12.5
LTCO
Buy
pSivida data on Durasert provide basis for NDA filing, says Ladenburg
Ladenburg analyst Matthew Kaplan was "impressed" with the results from pSivida's second Phase 3 trial of Durasert, which he said strongly confirm the efficacy and safety seen in the earlier study and can serve as the basis for a U.S. NDA filing. The company currently plans an NDA filing by Q4 and plans to commercialize Durasert via a contract sales organization, noted Kaplan, who reiterates a Buy rating and $12.50 price target on the stock, which is down 32c, or 15%, to $1.76 in afternoon trading.
05/30/17
RODM
05/30/17
INITIATION
Target $8
RODM
Buy
pSivida initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju started pSivida with a Buy rating and $8 price target.
12/04/17
RILY
12/04/17
INITIATION
Target $5
RILY
Buy
pSivida resumed with a Buy at B. Riley FBR
B. Riley FBR resumed coverage of pSivida with a Buy rating and $5 price target.
VTGN VistaGen Therapeutics
$1.19

0.08 (7.21%)

03/28/17
MAXM
03/28/17
INITIATION
Target $4
MAXM
Buy
VistaGen Therapeutics initiated with a Buy at Maxim
Maxim analyst Lauren Chung initiated VistaGen with a Buy rating and $4 price target, based on the opportunity for the company's AV-101, which is part of an emerging class of antidepressant drugs with the potential for rapid relief of depressive symptoms. VistaGen is now in a Phase 2 study that will help establish the safety profile for AV-101 and is designing a Phase 2 adjunctive therapy study that is expected to initiate in 2H17, Chung noted.
SPHS Sophiris Bio
$2.27

-0.13 (-5.42%)

ABMD Abiomed
$209.76

1.96 (0.94%)

10/26/17
PIPR
10/26/17
NO CHANGE
Target $200
PIPR
Overweight
Abiomed price target raised to $200 from $160 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Abiomed to $200 and "strongly" encourages investorts to build positions in the shares at current levels. The analyst views today's Q2 results as "impressive" and feels the company's earnings power is among the best in medical technology. O'Brien keeps an Overweight rating on Abiomed.
12/21/17
JEFF
12/21/17
NO CHANGE
JEFF
Jefferies lays out top 2018 ideas in Medical Supplies & Devices
Jefferies analyst Raj Denhoy calls Haemonetics (HAE), AxoGen (AXGN), Abbott (ABT) and Hologic (HOLX) his top Medical Supplies & Devices ideas to start 2018. Following a year of strong device performance in 2017, the analyst believes 2018 is "looking like more of the same." Denhoy raised his price target for Abiomed (ABMD) to $220, for Dexcom (DXCM) to $70, for Haemonetics to $68, for Hologic to $52, for LivaNova (LIVN) to $94, for Varex Imaging (VREX) to $44 and for Zimmer Biomet (ZBH) to $140. The analyst has Buy ratings on all of those stocks.
10/16/17
BTIG
10/16/17
DOWNGRADE
BTIG
Neutral
Abiomed downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded Abiomed to Neutral from Buy citing valuation after the stock's 70% move higher over the last year. He feels that at over $170 shares are fairly valued and may be pricing in strong quarterly results and a successful STEMI DTU trial.
01/04/18
PIPR
01/04/18
NO CHANGE
Target $220
PIPR
Overweight
Piper says buy Abiomed at these levels, ups price target to $220
Piper Jaffray analyst Matt O'Brien raised his price target for Abiomed to $220 from $200 and says the shares should be bought, "even at these levels." Investors do not fully comprehend the importance of a surgeon led "Call to Action" to improve outcomes in cardiogenic shock rates, which have not improved in 20 years, O'Brien tells investors in a research note. The analyst continues to believe Abiomed is the best "open-ended growth story" in all of med tech and he "strongly" recommends investors start or build positions in the name.
AYTU Aytu BioScience
$2.36

-0.11 (-4.45%)

TROV Trovagene
$0.34

-0.0175 (-4.90%)

11/10/17
11/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. MetLife (MET) downgraded to Hold from Buy at Sandler O'Neill. 2. Johnson Controls (JCI) downgraded to Hold from Buy at Vertical Research with analyst Jeffery Sprague telling investors shares are "stuck in Purgatory." 3. Trovagene (TROV) downgraded to Hold from Buy at Maxim with analyst Jason Kolbert saying Trovagene needs to raise capital in order to gain a stronger position to transition to a therapeutics company focused on PCM-075. 4. Esterline (ESL) was downgraded to Hold from Buy at Drexel Hamilton and to Hold from Buy at SunTrust. 5. Marathon Oil (MRO) downgraded to Neutral from Buy at Citi with analyst Robert Morris citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/10/17
MAXM
11/10/17
DOWNGRADE
MAXM
Hold
Trovagene downgraded to Hold from Buy at Maxim
As reported earlier, Maxim analyst Jason Kolbert downgraded Trovagene to Hold from Buy and removed his $4 price target. Kolbert says the company closed Q3 with $7.4M in cash, which is likely to be much lower today. The analyst says Trovagene needs to raise capital in order to gain a stronger position to transition to a therapeutics company focused on PCM-075.
11/10/17
MAXM
11/10/17
DOWNGRADE
MAXM
Hold
Trovagene downgraded to Hold from Buy at Maxim
12/21/17
HCWC
12/21/17
INITIATION
Target $1
HCWC
Buy
Trovagene initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Trovagene with a Buy rating and $1 price target. The analyst believes the company's PCM-075 is differentiated from other ATP-competitive PLK1 inhibitors.
KOOL Cesca Therapeutics
$3.79

0.4383 (13.08%)

SFE Safeguard Scientifics
$11.05

(0.00%)

12/07/17
KBWI
12/07/17
INITIATION
Target $13.25
KBWI
Market Perform
Safeguard Scientifics assumed with a Market Perform at Keefe Bruyette
Keefe Bruyette analyst Robert Lee assumed coverage on Safeguard Scientifics with a Market Perform and $13.25 price target.

TODAY'S FREE FLY STORIES

SNPS

Synopsys

$90.29

1.05 (1.18%)

21:14
05/23/18
05/23
21:14
05/23/18
21:14
Recommendations
Synopsys analyst commentary at JPMorgan »

Synopsys benefited from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AMZN

Amazon.com

$1,601.77

19.67 (1.24%)

21:04
05/23/18
05/23
21:04
05/23/18
21:04
Periodicals
Amazon Web Services to invest in Chile as part of LatAm expansion, Reuters says »

Amazon Web Services is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

SRRK

Scholar Rock

$0.00

(0.00%)

21:01
05/23/18
05/23
21:01
05/23/18
21:01
Syndicate
Scholar Rock 5.36M share IPO priced at $14.00 »

The deal priced in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

KNSA

Kiniksa

$0.00

(0.00%)

21:00
05/23/18
05/23
21:00
05/23/18
21:00
Syndicate
Kiniksa 8.5M share IPO priced at $18.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

GSKY

GreenSky

$0.00

(0.00%)

20:58
05/23/18
05/23
20:58
05/23/18
20:58
Syndicate
GreenSky 38M share IPO priced at $23.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

SAIL

SailPoint

$23.30

1.29 (5.86%)

20:56
05/23/18
05/23
20:56
05/23/18
20:56
Syndicate
SailPoint 17.808M share Secondary priced at $22.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

CLPS

CLPS

$0.00

(0.00%)

20:55
05/23/18
05/23
20:55
05/23/18
20:55
Syndicate
CLPS 2M share IPO priced at $5.25 »

The deal priced between…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

MDT

Medtronic

$85.29

0.305 (0.36%)

, MCK

McKesson

$146.84

0.39 (0.27%)

20:25
05/23/18
05/23
20:25
05/23/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MDT

Medtronic

$85.29

0.305 (0.36%)

MCK

McKesson

$146.84

0.39 (0.27%)

BBY

Best Buy

$75.73

0.255 (0.34%)

HRL

Hormel Foods

$35.82

-0.01 (-0.03%)

TTC

Toro Company

$60.32

-0.08 (-0.13%)

SAFM

Sanderson Farms

$107.13

1.19 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 24

    May

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 02

    Jun

  • 05

    Jun

  • 12

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

BPOP

Popular

$46.94

-0.31 (-0.66%)

20:07
05/23/18
05/23
20:07
05/23/18
20:07
Hot Stocks
Popular announces early termination of FDIC shared-loss agreements »

Popular, Inc announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSM

Williams-Sonoma

$49.21

1.91 (4.04%)

20:04
05/23/18
05/23
20:04
05/23/18
20:04
Recommendations
Williams-Sonoma analyst commentary at Loop Capital »

Williams-Sonoma earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

EWY

iShares MSCI South Korea Index Fund

$74.45

0.73 (0.99%)

, SPY

SPDR S&P 500 ETF Trust

$273.37

0.8 (0.29%)

19:59
05/23/18
05/23
19:59
05/23/18
19:59
Periodicals
Breaking Periodicals news story on iShares MSCI South Korea Index Fund, SPDR S&P 500 ETF Trust, S&P 500 »

N Korea foreign ministry…

EWY

iShares MSCI South Korea Index Fund

$74.45

0.73 (0.99%)

SPY

SPDR S&P 500 ETF Trust

$273.37

0.8 (0.29%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$128.70

0.465 (0.36%)

19:39
05/23/18
05/23
19:39
05/23/18
19:39
Hot Stocks
Canadian court affirms dismissal of suit against Chevron subsidiary »

The Ontario Court of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EA

Electronic Arts

$133.49

1.31 (0.99%)

19:19
05/23/18
05/23
19:19
05/23/18
19:19
Hot Stocks
Electronic Arts CTO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$64.67

-0.39 (-0.60%)

19:14
05/23/18
05/23
19:14
05/23/18
19:14
Periodicals
Carnival CEO expects China to become the largest cruise market, CNBC says »

In an interview with CNBC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

PBR

Petrobras

$15.10

-0.6 (-3.82%)

19:11
05/23/18
05/23
19:11
05/23/18
19:11
Periodicals
Petrobras slashes diesel price 10% to resolve trucker protest, Reuters says »

Petrobras has opted to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$88.94

-0.24 (-0.27%)

19:05
05/23/18
05/23
19:05
05/23/18
19:05
Hot Stocks
Sarepta granted orphan status for DMD treatment golodirsen »

The FDA granted Sarepta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

BZLFF

Bunzl

$0.00

(0.00%)

19:03
05/23/18
05/23
19:03
05/23/18
19:03
Downgrade
Bunzl rating change at Goldman Sachs »

Bunzl downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WUBA

58.com

$84.56

1.39 (1.67%)

19:02
05/23/18
05/23
19:02
05/23/18
19:02
Earnings
Breaking Earnings news story on 58.com »

58.com sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 10

    Sep

WUBA

58.com

$84.56

1.39 (1.67%)

19:01
05/23/18
05/23
19:01
05/23/18
19:01
Earnings
58.com reports Q1 adjusted earnings per ADS 33c, consensus 21c »

Reports Q1 revenue $393M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 10

    Sep

WSM

Williams-Sonoma

$49.21

1.91 (4.04%)

, LASR

nLight

$30.00

-1.79 (-5.63%)

18:58
05/23/18
05/23
18:58
05/23/18
18:58
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

WSM

Williams-Sonoma

$49.21

1.91 (4.04%)

LASR

nLight

$30.00

-1.79 (-5.63%)

SNPS

Synopsys

$90.29

1.05 (1.18%)

LB

L Brands

$34.05

0.06 (0.18%)

NTAP

NetApp

$66.61

-0.41 (-0.61%)

DGLY

Digital Ally

$2.55

-0.075 (-2.86%)

FCAU

Fiat Chrysler

$22.47

-0.155 (-0.69%)

TM

Toyota

$134.85

-0.89 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 11

    Jun

  • 12

    Jun

  • 10

    Jul

CPRT

Copart

$52.93

-0.06 (-0.11%)

18:54
05/23/18
05/23
18:54
05/23/18
18:54
Earnings
Copart reports Q3 adjusted EPS 52c, consensus 50c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

AAPL

Apple

$188.36

1.08 (0.58%)

, VLKAY

Volkswagen

$0.00

(0.00%)

18:45
05/23/18
05/23
18:45
05/23/18
18:45
Periodicals
Apple signs pact with VW over self-driving cars, NY Times says »

Apple (AAPL) has signed…

AAPL

Apple

$188.36

1.08 (0.58%)

VLKAY

Volkswagen

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$15.10

-0.6 (-3.82%)

18:24
05/23/18
05/23
18:24
05/23/18
18:24
Periodicals
Breaking Periodicals news story on Petrobras »

Petrobras under scrutiny…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$344.70

13.08 (3.94%)

, CMCSA

Comcast

$31.87

-0.64 (-1.97%)

18:03
05/23/18
05/23
18:03
05/23/18
18:03
Periodicals
Netflix market value now higher than Comcast, Recode says »

Netflix's (NFLX)…

NFLX

Netflix

$344.70

13.08 (3.94%)

CMCSA

Comcast

$31.87

-0.64 (-1.97%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$113.87

-0.05 (-0.04%)

18:01
05/23/18
05/23
18:01
05/23/18
18:01
Hot Stocks
Celanese to increase selling prices on acetyl intermediate products »

To raise prices on Vinyl…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.